Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaprazan glurate versus lansoprazole for maintenance of healed erosive esophagitis
2025-522750-39-00Phase 3Completed
- Sponsor
- Cinclus Pharma
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of linaprazan glurate and lansoprazole in erosive esophagitis (EE) and gastroesophageal reflux disease (GERD) (3 arms), sponsored by Cinclus Pharma. Primary endpoint: Maintained healing of erosive esophagitis after 24 weeks. Started Apr 2026; status: completed.
02
Drugs
linaprazan gluratelansoprazole
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2025-522750-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522750-39-00.